Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 5
2011 3
2012 2
2014 4
2015 7
2016 8
2017 2
2018 4
2019 4
2020 3
2021 1
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T, Nevedomskaya E, Heller S, Böhme A, Lesche R, von Ahsen O, Grünewald S, Nguyen HM, Corey E, Baumgart SJ, Georgi V, Pütter V, Fernández-Montalván A, Vasta JD, Robers MB, Politz O, Mumberg D, Haendler B. Sugawara T, et al. Among authors: nevedomskaya e. Mol Oncol. 2024 Mar;18(3):726-742. doi: 10.1002/1878-0261.13577. Epub 2024 Jan 15. Mol Oncol. 2024. PMID: 38225213 Free PMC article.
Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.
Linder S, Severson TM, van der Mijn KJC, Nevedomskaya E, Siefert JC, Stelloo S, Pomerantz MM, Freedman ML, van der Poel H, Jerónimo C, Henrique R, Bergman AM, Zwart W. Linder S, et al. Among authors: nevedomskaya e. Eur Urol. 2023 Nov;84(5):455-460. doi: 10.1016/j.eururo.2023.05.032. Epub 2023 Jun 2. Eur Urol. 2023. PMID: 37271632
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models.
Lemos C, Schulze VK, Baumgart SJ, Nevedomskaya E, Heinrich T, Lefranc J, Bader B, Christ CD, Briem H, Kuhnke LP, Holton SJ, Bömer U, Lienau P, von Nussbaum F, Nising CF, Bauser M, Hägebarth A, Mumberg D, Haendler B. Lemos C, et al. Among authors: nevedomskaya e. Cell Oncol (Dordr). 2021 Jun;44(3):581-594. doi: 10.1007/s13402-020-00584-8. Epub 2021 Jan 25. Cell Oncol (Dordr). 2021. PMID: 33492659
Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target.
Brzezinka K, Nevedomskaya E, Lesche R, Haegebarth A, Ter Laak A, Fernández-Montalván AE, Eberspaecher U, Werbeck ND, Moenning U, Siegel S, Haendler B, Eheim AL, Stresemann C. Brzezinka K, et al. Among authors: nevedomskaya e. Cancers (Basel). 2020 Jan 14;12(1):201. doi: 10.3390/cancers12010201. Cancers (Basel). 2020. PMID: 31947537 Free PMC article.
46 results